Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Colorectal Neoplasms × ascrinvacumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Camurati-Engelmann Syndrome 1

Interventions

Oxaliplatin 239 Bevacizumab 229 Fluorouracil 226 Irinotecan 213 Leucovorin 195 Capecitabine 172 Cetuximab 144 Folfox protocol 63 Colonoscopy 63 regorafenib 58 Panitumumab 56 Drug Therapy 46 Blood Specimen Collection 45 Radiotherapy 44 HMPL-013 40 trifluridine tipiracil drug combination 37 pembrolizumab 35 Surveys and Questionnaires 32 Neoadjuvant Therapy 32 Standard of Care 30 Surgical Procedures, Operative 29 Nivolumab 28 IFL protocol 27 Magnetic Resonance Spectroscopy 25 Interviews as Topic 24 XELOX 23 Methods 22 Early Intervention, Educational 22 Cyclophosphamide 22 Celecoxib 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02116894 2019-03-14

REGAL-1

Duke University

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡